Clay Thorp

Clay Bernardin Thorp is the founder of PhaseBio Pharmaceuticals, Inc., founded in 2002, serving as Chairman since 2014.
Mr. Thorp is the founder of Hatteras Venture Partners, founded in 2000, serving as General Partner since 2000.
Mr. Thorp is also the founder of Synthematix, Inc.,Karo Bio USA, Inc.,Xanthon, Inc...
Mr. Thorp is Chairman at Clearside Biomedical, Inc. since 2012.
Mr. Thorp is Director at GeneCentric Therapeutics, Inc., Rodin Therapeutics, Inc., Curoverse, Inc., Seaport Diagnostics, Inc., StrideBio, Inc., and North Carolina School of Science & Mathematics Foundation.
Mr. Thorp is Member-Visitors Board at Lineberger Comprehensive Cancer Center.
Mr. Thorp was Director at CancerGuide Diagnostics, Inc., Device Innovation Group LLC, Pathfinder Therapeutics, Inc., G1 Therapeutics, Inc., Lysosomal Therapeutics, Inc., and Vigil Neuroscience, Inc. from 2020 to 2022.
Mr. Thorp was Advisor at Research Triangle Ventures LLC.
Mr. Thorp completed graduate studies at Harvard University in 1994.
Mr. Thorp completed undergraduate studies at The University of North Carolina at Chapel Hill in 1990.